Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于公司2022年度计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's 2022 annual asset impairment provision. It includes specific financial figures for impairment losses on various asset categories, explanations of accounting policies and methods for impairment recognition, and approvals from the board, independent directors, and supervisory board. The document references compliance with accounting standards and includes audit confirmation by an accounting firm. It is not a full annual report but a specific announcement about asset impairment provisions for the fiscal year 2022. The document length is 6703 characters, which is substantial and contains detailed financial and accounting information, not just a brief announcement or certification. Therefore, it fits best under Audit Report / Information (AR), as it is a standalone audit-related announcement about asset impairment provisions and accounting treatments, rather than a full annual report or other categories. FY 2022
2023-04-21 Chinese
独立董事关于第九届董事会第九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on several matters to be discussed at the ninth meeting of the ninth board of directors. It includes opinions on related party transactions, guarantees within the consolidated financial statements, and the appointment of an accounting firm for the 2023 audit. The content is focused on governance and board-level approvals rather than financial results or detailed reports. It does not contain financial statements or detailed financial data, nor is it a transcript or announcement of voting results. The document aligns with Board/Management Information (MANG) as it relates to board meeting matters and approvals by directors.
2023-04-21 Chinese
独立董事关于第九届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters related to the company's 2022 fiscal year and proposals to be submitted to the 2022 annual shareholders' meeting. It covers profit distribution plans, related party transactions, internal control self-assessment, asset impairment provisions, and appointment of auditors. The document is not a full annual report or financial statement but rather an opinion and review related to board meeting matters and proposals for shareholder approval. It aligns with the type of Board/Management Information (MANG) filings, which include announcements of board meeting decisions and related opinions. The document length is short (2306 characters), and it is not a report publication announcement or certification. Therefore, the best classification is MANG.
2023-04-21 Chinese
2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Report Summary" of 广州市香雪制药股份有限公司 (Guangzhou Xiangxue Pharmaceutical Co., Ltd.). It contains detailed financial data for the year 2022, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, and legal proceedings. The document references the auditor's opinion (standard unqualified opinion) and includes comprehensive financial and operational information typical of an annual report. The length of the document (7079 characters) and the detailed financial and business content confirm it is the actual report, not just an announcement or summary notice. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding the use of funds by controlling shareholders and other related parties for Guangzhou Xiangxue Pharmaceutical Co., Ltd. It references an audit conducted by Da Hua Certified Public Accountants, including the 2022 financial statements and an audit report with an unqualified opinion. The document specifically addresses non-operating fund occupation and related party transactions for the fiscal year ending December 31, 2022. It cites regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding disclosure of such related party transactions. The document includes detailed tables summarizing the non-operating fund occupation and other related party fund transactions. This type of document is a standalone audit-related report focusing on specific regulatory disclosures about related party transactions and fund occupation, not a full annual report or general financial statement. It fits the category of Audit Report / Information (AR) as it is a special audit-related disclosure report issued by the auditor, separate from the full annual report (10-K). The document length (5625 characters) and content confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-21 Chinese
关于公司合并报表范围内担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the guarantee limits within the scope of consolidated financial statements. It details the guarantee amounts between the company and its subsidiaries, financial data of the subsidiaries, board and supervisory opinions, and independent directors' opinions. The document is not a full financial report but a specific corporate announcement about financing guarantees and related approvals. It does not contain comprehensive financial statements or quarterly/yearly financial results but focuses on guarantee limits and related corporate governance approvals. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantee arrangements within the group. The document length (8324 characters) supports it being a detailed announcement rather than a brief notice or a full annual/interim report.
2023-04-21 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.